



**Commercial/Healthcare Exchange Quantity Limit Criteria**  
*Effective: November 13, 2019*

**Quantity Limit Name:** GVOKE (glucagon) subcutaneous injection

**Products Affected:** GVOKE HypoPen, GVOKE PFS

**Type of Quantity Limit:**

- FDA maximum
- Usual Daily Frequency
- Split fill
- Other (Please specify): \_\_\_\_\_

**Limits to be applied:**

GVOKE (glucagon) 1mg/0.2mL subcutaneous injection  
GVOKE (glucagon) 0.5mg/0.1mL subcutaneous injection

Quantity Limit: 2 syringes/auto-injectors per claim  
Quantity Limit: 2 syringes/auto-injectors per claim

**References:**

1. Gvoke [package insert]. Chicago, IL; Xeris Pharmaceuticals Inc; October 2019.

**Policy Revision history**

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	11/13/2019